









Markets
/
Stocks
/
nasdaq-orgo
/

Organogenesis Holdings Inc

ORGO

5.630USD

+1.740+44.73%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

714.51MMarket Cap

LossP/E TTM



Organogenesis Holdings Inc

5.630

+1.740+44.73%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Organogenesis Holdings Inc

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Organogenesis Holdings Inc's Score

Industry at a Glance

Industry Ranking

27 / 407

Overall Ranking

107 / 4614

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Strong Buy

Current Rating

8.000

Target Price

+42.10%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Organogenesis Holdings Inc Highlights

StrengthsRisks

Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Its advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier and native, cross-linked extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types. Sports Medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for management of open wounds in the surgical setting.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Undervalued

The company’s latest PE is -75.22, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 72.04M shares, decreasing 0.93% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 5.20M shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 8.87, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 150.49M, representing a year-over-year increase of 30.66%, while its net profit experienced a year-over-year increase of 17.79%.

Score

Industry at a Glance

Previous score

8.87

Change



Financials

7.48

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.28

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.58

Key Metrics

Free cash flow

No Data

Organogenesis Holdings Inc's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 6.30, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -75.22, which is -258.42% below the recent high of 119.16 and -1059.56% above the recent low of -872.19.

Score

Industry at a Glance

Previous score

6.30

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 27/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 9.00, which is higher than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Organogenesis Holdings Inc is 8.00, with a high of 9.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Strong Buy

Current Rating

8.000

Target Price

+42.10%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Organogenesis Holdings Inc

ORGO

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 9.29, which is higher than the Biotechnology & Medical Research industry's average of 6.46. Sideways: Currently, the stock price is trading between the resistance level at 6.61 and the support level at 4.25, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.39

Change

2.9

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.201

Neutral

RSI(14)

76.184

Buy

STOCH(KDJ)(9,3,3)

45.850

Buy

ATR(14)

0.345

High Vlolatility

CCI(14)

439.571

Overbought

Williams %R

24.153

Buy

TRIX(12,20)

-0.119

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

4.274

Buy

MA10

4.249

Buy

MA20

4.161

Buy

MA50

4.428

Buy

MA100

4.417

Buy

MA200

4.212

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 56.78%, representing a quarter-over-quarter decrease of 43.53%. The largest institutional shareholder is The Vanguard, holding a total of 5.20M shares, representing 4.10% of shares outstanding, with 43.48% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Soleus Capital Management, L.P.

12.34M

-1.08%

Nussdorf (Glenn H)

11.91M

Morgan Stanley & Co. LLC

11.98M

-0.42%

Ades (Alan A)

11.19M

Erani (Dennis)

10.04M

Organo PFG LLC

8.28M

RED Holdings, L.L.C.

6.78M

First Light Asset Management, LLC

6.78M

The Vanguard Group, Inc.

Star Investors

5.20M

+17.27%

Assenagon Asset Management S.A.

4.85M

+69.88%

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 4.27, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.51. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.